A new trading day began on Monday, with Rocket Pharmaceuticals Inc (NASDAQ: RCKT) stock price down -12.12% from the previous day of trading, before settling in for the closing price of $7.59. RCKT’s price has ranged from $7.48 to $26.99 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 10.43%. With a float of $98.97 million, this company’s outstanding shares have now reached $106.45 million.
Let’s look at the performance matrix of the company that is accounted for 299 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Rocket Pharmaceuticals Inc (RCKT) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Rocket Pharmaceuticals Inc is 7.18%, while institutional ownership is 101.05%. The most recent insider transaction that took place on Feb 25 ’25, was worth 69,109. In this transaction an insider of this company sold 6,532 shares at a rate of $10.58, taking the stock ownership to the 237,638 shares. Before that another transaction happened on May 17 ’24, when Company’s insider sold 2,754 for $23.35, making the entire transaction worth $64,306. This insider now owns 169,659 shares in total.
Rocket Pharmaceuticals Inc (RCKT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.59 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 73.89% during the next five years compared to -11.60% drop over the previous five years of trading.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Trading Performance Indicators
Here are Rocket Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -1.59 in one year’s time.
Technical Analysis of Rocket Pharmaceuticals Inc (RCKT)
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) saw its 5-day average volume 2.61 million, a positive change from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 14.56%. Additionally, its Average True Range was 0.57.
During the past 100 days, Rocket Pharmaceuticals Inc’s (RCKT) raw stochastic average was set at 3.44%, which indicates a significant decrease from 15.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.53% in the past 14 days, which was higher than the 56.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.55, while its 200-day Moving Average is $15.66. Nevertheless, the first resistance level for the watch stands at $7.21 in the near term. At $7.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.23. If the price goes on to break the first support level at $6.20, it is likely to go to the next support level at $5.72. The third support level lies at $5.18 if the price breaches the second support level.
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) Key Stats
With a market capitalization of 711.22 million, the company has a total of 106,630K Shares Outstanding. Currently, annual sales are 0 K while annual income is -258,750 K. The company’s previous quarter sales were 0 K while its latest quarter income was -60,330 K.
